Filing Details
- Accession Number:
- 0001209191-20-013029
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-02-26 16:34:08
- Reporting Period:
- 2020-02-24
- Accepted Time:
- 2020-02-26 16:34:08
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1242825 | M Jeffrey Leiden | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Ceo & President | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2020-02-24 | 8,410 | $239.23 | 103,131 | No | 4 | F | Direct | |
Common Stock | Disposition | 2020-02-25 | 2,273 | $229.77 | 100,858 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-02-25 | 1,120 | $230.40 | 99,738 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-02-25 | 1,050 | $231.76 | 98,688 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-02-25 | 1,017 | $232.96 | 97,671 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-02-25 | 1,640 | $234.49 | 96,031 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-02-25 | 1,210 | $235.53 | 94,821 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-02-25 | 560 | $236.63 | 94,261 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-02-25 | 1,680 | $238.33 | 92,581 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | F | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 440 | Indirect | 401(k) |
Footnotes
- Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1.
- Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $229.77 (range $229.07 to $230.00).
- Open market sales reported on this line occurred at a weighted average price of $230.40 (range $230.14 to $230.73).
- Open market sales reported on this line occurred at a weighted average price of $231.76 (range $231.27 to $232.14).
- Open market sales reported on this line occurred at a weighted average price of $232.96 (range $232.27 to $233.11).
- Open market sales reported on this line occurred at a weighted average price of $234.49 (range $233.99 to $234.66).
- Open market sales reported on this line occurred at a weighted average price of $235.53 (range $235.07 to $235.72).
- Open market sales reported on this line occurred at a weighted average price of $238.33 (range $238.16 to $238.56).